1.00Open0.90Pre Close42 Volume487 Open Interest6.00Strike Price4.41KTurnover270.80%IV41.47%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier27DDays to Expiry1.13Extrinsic Value100Contract SizeAmericanOptions Type0.5535Delta0.1068Gamma4.38Leverage Ratio-0.0277Theta0.0012Rho2.43Eff Leverage0.0054Vega
Candel Therapeutics Stock Discussion
5.30+
Now Let's Get That 10.+ Back!
Let's Get 5.+
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
Candel Therapeutics announced preclinical results for CAN-3110 in melanoma models, showing potential expansion beyond high-grade glioma treatment. CAN-3110, a first-in-class HSV-1 oncolytic viral immunotherapy, demonstrated potent antitumor activity in both in vitro human cel...
No comment yet